Binds A Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 435/335)
-
Publication number: 20130164256Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: October 24, 2012Publication date: June 27, 2013Applicant: ABBVIE INC.Inventors: Chung-Ming Hsieh, Tariq Ghayur, Lorenzo Benatuil, Yuliya Kutskova, John Memmott, Jennifer Perez, Suju Zhong, Carrie Goodreau, Anca Clabbers
-
Publication number: 20130142808Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.Type: ApplicationFiled: April 5, 2011Publication date: June 6, 2013Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
-
Patent number: 8455629Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: GrantFiled: January 27, 2012Date of Patent: June 4, 2013Assignees: Amgen Inc., Medarex, Inc.Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
-
Publication number: 20130102030Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: October 1, 2012Publication date: April 25, 2013Applicant: UCB PHARMA S.A.Inventor: UCB PHARMA S.A.
-
Publication number: 20130101595Abstract: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: September 5, 2012Publication date: April 25, 2013Applicant: Abbott LaboratoriesInventors: Tariq Ghayer, Richard W. Dixon, Michael Roguska, Michael White, Boris Labkovsky, Jochen Salfeld, Alexander Robert Duncan, Simon Mark Brocklehurst, John Mankovich, Celia Patricia Shorrock, Julia Elizabeth Thompson, Simon Nicholas Lennard
-
Publication number: 20130078237Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Inventors: John M. DELANEY, William Christian FANSLOW, III, Chadwick Terence KING
-
Patent number: 8404233Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.Type: GrantFiled: May 15, 2008Date of Patent: March 26, 2013Assignee: Smart Targeting LimitedInventors: Makoto Sunamura, Hideo Yagita
-
Publication number: 20130071923Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.Type: ApplicationFiled: August 20, 2012Publication date: March 21, 2013Applicant: Amgen Inc.Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
-
Patent number: 8399250Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: April 27, 1995Date of Patent: March 19, 2013Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8399630Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.Type: GrantFiled: August 11, 2009Date of Patent: March 19, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
-
Publication number: 20130046081Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.Type: ApplicationFiled: April 16, 2010Publication date: February 21, 2013Applicant: Shanghai Biomabs Pharmaceuticals Co., LTDInventors: Shuhui Wang, Chuan Li, Ying Kan, Xin Tong
-
Patent number: 8361790Abstract: The present invention relates to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, by using genetic engineering techniques. The human host cell with stable characteristics well preserved may be efficiently used to produce heterologous desired recombinant protein-based pharmaceuticals.Type: GrantFiled: April 10, 2009Date of Patent: January 29, 2013Assignee: Celltrion, Inc.Inventors: HyunJoo Lee, JongMook Kim, MinSeok Chang
-
Publication number: 20130022616Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: ApplicationFiled: June 28, 2012Publication date: January 24, 2013Applicant: Pfizer Inc.Inventors: Gary F. Bammert, Steven A. Dunham
-
Patent number: 8357782Abstract: The present invention has the first object to provide a monoclonal antibody specific to interferon ? subtype ?8 (IFN?8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFN?8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFN?8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFN?8.Type: GrantFiled: March 16, 2009Date of Patent: January 22, 2013Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Shigeharu Fukuda, Chie Ushio, Harumi Ariyasu, Tohru Kayano, Toshio Ariyasu, Tsunetaka Ohta
-
Publication number: 20130011412Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.Type: ApplicationFiled: July 6, 2012Publication date: January 10, 2013Applicant: Genentech, Inc.Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
-
Publication number: 20130004508Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: ApplicationFiled: June 25, 2012Publication date: January 3, 2013Applicant: SCHERING CORPORATIONInventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
-
Publication number: 20130005033Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 22, 2012Publication date: January 3, 2013Applicants: Wyeth LLC, MedImmune LimitedInventors: Davinder S. Gill, Jing Li, Geertruida M. Veldman, Lynette A. Fouser, Viia Valge-Archer, David C. Lowe, Caroline S. Russell, Suzanne E. Cohen, Albert G. Thom, Ralf R. Minter
-
Publication number: 20120329093Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: ApplicationFiled: July 2, 2012Publication date: December 27, 2012Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
-
Publication number: 20120294870Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.Type: ApplicationFiled: July 16, 2012Publication date: November 22, 2012Inventors: Vivian Takafuji, Xin Wei Wang, Edward J. Unsworth, Paul K. Goldsmith
-
Publication number: 20120282170Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: ApplicationFiled: July 12, 2012Publication date: November 8, 2012Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Publication number: 20120275996Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: ApplicationFiled: December 20, 2011Publication date: November 1, 2012Applicant: ABBOTT LABORATORIESInventor: Chung-ming Hsieh
-
Publication number: 20120269838Abstract: The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X1-S-D-I-F-X2-G-E-P-X3-L-X4-P-X5-X6-X7-X8-X9-Q-L (SEQ ID NO: 13).Type: ApplicationFiled: September 21, 2010Publication date: October 25, 2012Inventors: Jean-François Zagury, Rojo Ratsimandresy
-
Publication number: 20120269820Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: June 8, 2012Publication date: October 25, 2012Inventors: Krzysztof Masternak, Olivier Leger
-
Patent number: 8287861Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.Type: GrantFiled: June 30, 2009Date of Patent: October 16, 2012Assignee: Novo Nordisk A/SInventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
-
Patent number: 8278099Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: May 3, 1995Date of Patent: October 2, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. de Sauvage
-
Publication number: 20120244167Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: April 27, 2012Publication date: September 27, 2012Applicants: WARNER-LAMBERT COMPANY LLC, AMGEN FREMONT INC.Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20120244148Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: May 21, 2012Publication date: September 27, 2012Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Patent number: 8258266Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: GrantFiled: May 27, 2009Date of Patent: September 4, 2012Assignee: Medarex, Inc.Inventors: Shrikant Deshpande, Haichun Huang, Mohan Srinivasan, Josephine M. Cardarelli, Changyu Wang, David B. Passmore, Vangipuram Rangan, Thomas E. Lane, Hans S. Keirstead, Michael T. Liu
-
Publication number: 20120219565Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: ApplicationFiled: November 2, 2010Publication date: August 30, 2012Applicant: Schering CorporationInventor: Leonard G. Presta
-
Publication number: 20120213774Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.Type: ApplicationFiled: February 22, 2012Publication date: August 23, 2012Applicant: Hoffmann-La Roche Inc.Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
-
Publication number: 20120213799Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: ApplicationFiled: October 28, 2010Publication date: August 23, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Patent number: 8246953Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.Type: GrantFiled: November 11, 2010Date of Patent: August 21, 2012Assignee: Novartis AGInventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
-
Patent number: 8241900Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: April 13, 1995Date of Patent: August 14, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8241901Abstract: A method of secretory expression of lysostaphin in Escherichia coli at high level, which comprises constructing a expression vector by cloning a sequence encoding a signal peptide which is suitable for secretory expression in Escherichia coli before part or whole gene sequence which encodes mature lysostaphin, and ligating the cloned sequence with a promoter; and transforming Escherichia coli with the expression vector, culturing and fermenting, and then isolating lysostaphin from the supernatant of the fermentation broth. The advantage of secretory expression is that the expression product can exist in the medium in an active form, and thus does not need the process for renaturation of the inclusion body; it is more easily to purify from the supernatant of the fermentation broth with high rate of recovery; and there is less contamination from the host's proteins.Type: GrantFiled: July 11, 2006Date of Patent: August 14, 2012Assignee: Shanghai Hi-Tech United Bio-Technological Research & Development Co., Ltd.Inventors: Qingshan Huang, Hairong Lu, Wanying Lu
-
Publication number: 20120202285Abstract: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.Type: ApplicationFiled: April 24, 2012Publication date: August 9, 2012Applicants: BRISTOL-MYERS SQUIBB COMPANY, PFIZER INC.Inventors: Arvind Rajpal, Madhav Devalaraja, Kristopher Toy, Lan Yang, Haichun Huang, Jun Zhang, Peter Brams, Brigitte Devaux, David B. Passmore
-
Publication number: 20120177655Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Publication number: 20120156198Abstract: The invention provides anti-IL-18R1 antibodies and methods of using the same.Type: ApplicationFiled: August 25, 2011Publication date: June 21, 2012Inventors: Michael Brandt, Jens Fischer, Stefan Jenewein, Klaus Kaluza, Eileen Samy, Stefan Seeber
-
Publication number: 20120157667Abstract: Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods.Type: ApplicationFiled: June 28, 2010Publication date: June 21, 2012Inventors: Qingfeng Chen, Jianzhu Chen
-
Publication number: 20120148490Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne NcNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Patent number: 8192946Abstract: Disclosed are methods and compositions for detecting pregnancy in an animal by means of assaying peptidase activity of one or more Pregnancy Associated Glycoproteins (PAGs). In certain aspects, methods also comprising use of an antibody that binds immunologically to a PAG that displays proteolytic activity are provided. Substrates of proteolytic PAGs are also provided, as are kits, and methods of use. Further, methods of purifying PAGs based on their proteolytic activity are also provided.Type: GrantFiled: April 10, 2009Date of Patent: June 5, 2012Assignee: The Curators of The University of MissouriInventors: Jonathan Green, Bhanu Prakash Telugu
-
Publication number: 20120135005Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.Type: ApplicationFiled: April 16, 2010Publication date: May 31, 2012Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
-
Patent number: 8188249Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: March 29, 2010Date of Patent: May 29, 2012Assignees: Amgen Fremont Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20120129219Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules.Type: ApplicationFiled: September 23, 2011Publication date: May 24, 2012Applicant: UCB PHARMA S.A.Inventors: Stephen Edward Rapecki, Andrew George Popplewell, Ralph Adams
-
Publication number: 20120121606Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Steven M. Ruben, Steven C. Barash, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Publication number: 20120100153Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT, LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20120093833Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.Type: ApplicationFiled: October 10, 2011Publication date: April 19, 2012Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas
-
Publication number: 20120076798Abstract: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.Type: ApplicationFiled: September 22, 2011Publication date: March 29, 2012Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LIMITEDInventors: Steven W. Granger, Shinichiro Kato, Carl F. Ware
-
Publication number: 20120064001Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: ApplicationFiled: September 6, 2011Publication date: March 15, 2012Applicants: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.Inventors: Anita Kavlie, Kyle Schlunegger
-
Publication number: 20120064077Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: September 26, 2011Publication date: March 15, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC.Inventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20120052073Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: ApplicationFiled: June 27, 2011Publication date: March 1, 2012Applicant: Medlmmune LimitedInventors: Larry L. Green, Qing Zhou, Bruce A. Keyt, Xiao-Dong Yang, Stephen Charles Emery, David Charles Blakey